RADX — Radiopharm Theranostics Limited

Is RADX overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Oversold As of November 17, 2026

Radiopharm Theranostics Limited (RADX) currently reads Oversold on the MarketMoodz overbought/oversold meter, as of November 17, 2026. The Healthcare name (Biotechnology) last closed at $0.77. The rating moved from Strong Oversold to Oversold on November 10, 2026.

See all oversold Healthcare stocks →

AI analysis

Radiopharm Theranostics operates in the high‑potential but high‑risk theranostics niche; upside depends heavily on clinical/regulatory progress, partnership/commercial milestones, and successful financing. Public disclosure and financial visibility appear limited, creating material uncertainty about cash runway and dilution risk. Sector flows currently favor large-cap, defensive pharma, which reduces risk appetite for small issuers. Near-term movement is likely to be driven by company‑specific news (trial data, partnerships, financings) and remains volatile. Longer‑term upside exists if lead assets clear regulatory hurdles and secure commercialization/reimbursement pathways, but downside is substantial absent such catalysts.

Key factors

  • Early-stage radiopharmaceutical/theranostics focus with potential clinical and commercial upside if lead programs progress
  • Lack of recent public filings and limited disclosed financials creates uncertainty around cash runway and operating liquidity
  • Sector dynamics favor large-cap pharma defensives, reducing near-term investor appetite for small-cap healthcare/theranostics
  • Readthroughs from specialty-care and at‑home treatment trends could expand distribution channels if products commercialize
  • Convertible-debt and financing activity in the diagnostics/biotech space increases the odds of dilution for mid/small-cap issuers
  • Low absolute share price and likely limited float suggest high volatility and potential for sharp moves on news or lack thereof

Risks

  • Insufficient cash runway or inability to raise non-dilutive financing leading to material dilution or operational cutbacks
  • Negative clinical or regulatory outcomes for lead programs that would materially impair value
  • Intense competition from large pharmaceutical and diagnostic companies with greater resources and established commercial channels
  • Poor liquidity and wide bid-ask spreads increasing execution risk for investors
  • Uncertain reimbursement environment for new radiopharmaceuticals and theranostics products
  • Limited public information and research coverage, increasing information asymmetry and downside surprise risk
  • Macro/sector rotation away from small-cap biopharma could depress valuation absent near-term positive catalysts

Latest MarketMoodz coverage

See today's live rating, score and targets

Members see the live hourly rating for RADX — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.